文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

口服来法莫林对比莫西沙星治疗成人社区获得性细菌性肺炎的早期临床应答:LEAP 2 随机临床试验

Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical Trial.
PubMed 文献 · JAMA · 2019-01-01

这项3期非劣效随机试验在19国99个中心纳入738例PORT风险II–IV级社区获得性细菌性肺炎成人患者,比较口服来法莫林5天与莫西沙星7天方案。来法莫林组与莫西沙星组96小时早期临床应答率均为90.8%(差异0.1%,单侧97.5%CI -4.4%至∞),达到非劣效。

要点

  • 5天口服来法莫林在96小时早期临床应答方面非劣效于7天口服莫西沙星(两组均为90.8%)。
  • 治愈访视时研究者评估临床应答成功率在改良意向治疗人群为来法莫林87.5% vs 莫西沙星89.1%。
  • 最常见的治疗中出现的不良事件为胃肠道事件,腹泻来法莫林组12.2% vs 莫西沙星组1.1%。

核心结论

  • 在社区获得性细菌性肺炎患者中,5天口服来法莫林在首剂后96小时早期临床应答方面非劣效于7天口服莫西沙星。

研究设计与样本

  • 3期、非劣效随机临床试验,在19个国家的99个中心开展,纳入18岁及以上、PORT风险等级II、III或IV级、影像学证实肺炎、急性起病、有3个及以上CABP症状且2个及以上生命体征异常的患者。
  • 患者按1:1随机接受口服来法莫林600 mg每12小时一次共5天(n=370)或莫西沙星400 mg每24小时一次共7天(n=368)。
  • 首例患者访视于2016年8月30日,随访30天,末次随访访视于2018年1月2日。
  • 共738例随机患者(平均年龄57.5岁;女性351例[47.6%];PORT风险III或IV级360例[48.8%]),707例(95.8%)完成试验。

主要发现

  • 早期临床应答率来法莫林组为90.8%,莫西沙星组为90.8%(差异0.1%[单侧97.5%CI -4.4%至∞])。
  • 治愈访视时研究者评估临床应答成功率在改良意向治疗人群为来法莫林组87.5% vs 莫西沙星组89.1%(差异-1.6%[单侧97.5%CI -6.3%至∞])。
  • 治愈访视时研究者评估临床应答成功率在临床可评估人群为来法莫林组89.7% vs 莫西沙星组93.6%(差异-3.9%[单侧97.5%CI -8.2%至∞])。
  • 最常见的治疗中出现的不良事件为胃肠道事件:腹泻来法莫林组45/368(12.2%)vs 莫西沙星组4/368(1.1%);恶心来法莫林组19/368(5.2%)vs 莫西沙星组7/368(1.9%)。

关键数值与推荐

  • 美国食品药品监督管理局(FDA)主要终点为首剂后96小时(24小时窗口内)意向治疗人群的早期临床应答,应答者定义为存活、4个CABP症状中2个及以上改善、任何CABP症状无恶化且未因当前CABP发作接受非研究抗菌药物。
  • 欧洲药品管理局共同主要终点(FDA次要终点)为治愈访视(末次给药后5–10天)时研究者评估的临床应答,分别在改良意向治疗人群和临床可评估人群中评估。
  • 早期临床应答和研究者评估临床应答的非劣效界值均为10%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: New antibacterials are needed to treat community-acquired bacterial pneumonia (CABP) because of growing antibacterial resistance and safety concerns with standard care. OBJECTIVE: To evaluate the efficacy and adverse events of a 5-day oral lefamulin regimen in patients with CABP. DESIGN, SETTING, AND PARTICIPANTS: A phase 3, noninferiority randomized clinical trial conducted at 99 sites in 19 countries that included adults aged 18 years or older with a Pneumonia Outcomes Research Team (PORT) risk class of II, III, or IV; radiographically documented pneumonia; acute illness; 3 or more CABP symptoms; and 2 or more vital sign abnormalities. The first patient visit was on August 30, 2016, and patients were followed up for 30 days; the final follow-up visit was on January 2, 2018. INTERVENTIONS: Patients were randomized 1:1 to receive oral lefamulin (600 mg every 12 hours for 5 days; n = 370) or moxifloxacin (400 mg every 24 hours for 7 days; n = 368). MAIN OUTCOMES AND MEASURES: The US Food and Drug Administration (FDA) primary end point was early clinical response at 96 hours (within a 24-hour window) after the first dose of either study drug in the intent-to-treat (ITT) population (all randomized patients). Responders were defined as alive, showing improvement in 2 or more of the 4 CABP symptoms, having no worsening of any CABP symptoms, and not receiving any nonstudy antibacterial drug for current CABP episode. The European Medicines Agency coprimary end points (FDA secondary end points) were investigator assessment of clinical response at test of cure (5-10 days after last dose) in the modified ITT population and in the clinically evaluable population. The noninferiority margin was 10% for early clinical response and investigator assessment of clinical response. RESULTS: Among 738 randomized patients (mean age, 57.5 years; 351 women [47.6%]; 360 had a PORT risk class of III or IV [48.8%]), 707 (95.8%) completed the trial. Early clinical response rates were 90.8% with lefamulin and 90.8% with moxifloxacin (difference, 0.1% [1-sided 97.5% CI, -4.4% to ∞]). Rates of investigator assessment of clinical response success were 87.5% with lefamulin and 89.1% with moxifloxacin in the modified ITT population (difference, -1.6% [1-sided 97.5% CI, -6.3% to ∞]) and 89.7% and 93.6%, respectively, in the clinically evaluable population (difference, -3.9% [1-sided 97.5% CI, -8.2% to ∞]) at test of cure. The most frequently reported treatment-emergent adverse events were gastrointestinal (diarrhea: 45/368 [12.2%] in lefamulin group and 4/368 [1.1%] in moxifloxacin group; nausea: 19/368 [5.2%] in lefamulin group and 7/368 [1.9%] in moxifloxacin group). CONCLUSIONS AND RELEVANCE: Among patients with CABP, 5-day oral lefamulin was noninferior to 7-day oral moxifloxacin with respect to early clinical response at 96 hours after first dose. TRIAL REGISTRATIONS: ClinicalTrials.gov Identifier: NCT02813694; European Clinical Trials Identifier: 2015-004782-92.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Alexander E, Goldberg L, Das AF, et al. Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical Trial. JAMA. 2019. PMID: 31560372. doi:10.1001/jama.2019.15468

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。